Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030

Got story updates? Submit your updates here. ›

The global market for decentralized clinical trials (DCTs) is projected to reach $18.8 billion by 2030, growing at a compound annual rate of 13.7% from 2025 to 2030. This growth is driven by favorable regulatory support, the proliferation of digital health infrastructure, and the demand for improved patient access and trial diversity.

Why it matters

Decentralized clinical trials are fundamentally changing how pharmaceutical and biotechnology companies develop new therapies, allowing them to reach patients in underserved and remote areas and address regulatory expectations for more representative study populations. The integration of AI and wearable technologies is creating new capabilities that are reshaping the competitive landscape.

The details

The DCT market was valued at $8.8 billion in 2024 and is expected to reach $18.8 billion by 2030. Key market segments include interventional trials, observational trials, and expanded access programs, with cloud-based platforms leading deployment. The market is driven by favorable regulatory support, the proliferation of digital health infrastructure, and the demand for improved patient access and trial diversity. Technology advancements, including AI and wearables, are creating new capabilities and intensifying competition as companies seek to build comprehensive DCT capabilities.

• The global DCT market was valued at $8.8 billion in 2024.
• The DCT market is projected to reach $18.8 billion by the end of 2030.
• The market is expected to grow at a compound annual growth rate (CAGR) of 13.7% from 2025 through 2030.